ALKS

55.14

1.03% 0.56

Vorhandelsmarkt: 56.75 1.61 +2.92%

Alkermes Plc (ALKS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALKS? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$54.58

Offen:

$54.03

24-Stunden-Volumen:

1.74M

Relative Volume:

0.71

Marktkapitalisierung:

$9.19B

Einnahmen:

$1.56B

Nettoeinkommen (Verlust:

$152.72M

KGV:

61.31

EPS:

0.8994

Netto-Cashflow:

$221.80M

1W Leistung:

+4.97%

1M Leistung:

+28.83%

6M Leistung:

+91.59%

1J Leistung:

+91.13%

1-Tages-Spanne:

$53.41

$55.37

1-Wochen-Bereich:

$50.96

$55.37

52-Wochen-Spanne:

$25.16

$55.37

Alkermes Plc Stock (ALKS) Company Profile

Firmenname

Alkermes Plc

Sektor

Healthcare (1100)

Branche

Drug Manufacturers - Specialty & Generic (86)

Telefon

00-353-1-772-8000

Adresse

CONNAUGHT HOUSE, DUBLIN 4

Mitarbeiter

2,050

Twitter

@alkermes

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

ALKS's Discussions on Twitter

Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALKS Alkermes Plc	55.14	8.73B	1.56B	152.72M	221.80M	0.8994
TAK Takeda Pharmaceutical Co Adr	16.89	50.65B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.72	41.09B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.29	39.45B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.42	30.13B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.25	23.00B	3.17B	1.29B	1.01B	27.09

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-24	Eingeleitet	Wolfe Research	Outperform
2025-11-11	Eingeleitet	Truist	Buy
2025-09-26	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2025-09-03	Eingeleitet	Wells Fargo	Overweight
2025-07-15	Eingeleitet	Goldman	Buy
2025-06-17	Hochstufung	UBS	Neutral → Buy
2025-05-28	Eingeleitet	Needham	Buy
2025-03-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2025-03-04	Hochstufung	UBS	Sell → Neutral
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-11-05	Hochstufung	Stifel	Hold → Buy
2024-06-17	Eingeleitet	TD Cowen	Buy
2024-03-19	Eingeleitet	Robert W. Baird	Outperform
2024-02-20	Herabstufung	UBS	Neutral → Sell
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-10-24	Hochstufung	Evercore ISI	In-line → Outperform
2023-10-17	Eingeleitet	UBS	Neutral
2022-11-03	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-14	Hochstufung	BofA Securities	Underperform → Neutral
2022-08-16	Eingeleitet	Piper Sandler	Neutral
2022-04-22	Fortgesetzt	Goldman	Buy
2022-04-20	Eingeleitet	Goldman	Buy
2022-01-27	Hochstufung	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Eingeleitet	Citigroup	Neutral
2021-10-07	Hochstufung	Jefferies	Hold → Buy
2021-09-02	Herabstufung	BofA Securities	Neutral → Underperform
2020-10-15	Hochstufung	Mizuho	Neutral → Buy
2020-07-30	Herabstufung	Goldman	Neutral → Sell
2020-02-14	Herabstufung	BofA/Merrill	Buy → Neutral
2020-02-14	Bestätigt	H.C. Wainwright	Neutral
2020-02-14	Herabstufung	JP Morgan	Overweight → Neutral
2020-02-06	Eingeleitet	Mizuho	Neutral
2020-01-31	Hochstufung	Wolfe Research	Underperform → Peer Perform
2019-09-05	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Hochstufung	Goldman	Sell → Neutral
2019-05-31	Eingeleitet	H.C. Wainwright	Neutral
2019-05-01	Herabstufung	Citigroup	Buy → Neutral
2018-12-19	Herabstufung	Goldman	Neutral → Sell
2018-12-14	Eingeleitet	Wolfe Research	Underperform
2018-12-13	Herabstufung	Credit Suisse	Outperform → Underperform
2018-11-05	Eingeleitet	Piper Jaffray	Neutral
2018-08-07	Eingeleitet	Stifel	Hold
2018-06-21	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Eingeleitet	B. Riley FBR, Inc.	Buy
2018-05-16	Hochstufung	Citigroup	Neutral → Buy
2018-05-11	Eingeleitet	BofA/Merrill	Buy

Alle ansehen

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

Jul 01, 2026

Alkermes (ALKS) R&D chief exercises 5,000 options and sells 9,000 shares - Stock Titan

Jul 01, 2026

Alkermes (ALKS) shows multiple 9,000-share insider sales, exercise and vesting - Stock Titan

Jul 01, 2026

Jun 30, 2026

ALKSAlkermes plc Latest SEC Filings - Finviz

Jun 30, 2026

Alkermes (ALKS) Is Up 9.3% After Strong Alixorexton Phase 2 Data And Russell 2000 AdditionWhat's Changed - Yahoo Finance

Jun 30, 2026

Jun 29, 2026

BofA downgrades Alkermes stock rating on valuation concerns By Investing.com - Investing.com Australia

Jun 29, 2026

BofA downgrades Alkermes stock rating on valuation concerns - Investing.com

Jun 29, 2026

REGBlackRock GroupSAR 6ALKERMES PLC - TradingView

Jun 29, 2026

Jun 28, 2026

Enterprise value to EBIT forward of Alkermes plc – NASDAQ:ALKS - TradingView

Jun 28, 2026

Press Release: Alkermes to Report First Quarter Financial Results on May 5, 2026 - Moomoo

Jun 28, 2026

Jun 27, 2026

Price to sales forward of Alkermes plc – NASDAQ:ALKS - TradingView

Jun 27, 2026

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits

Jun 27, 2026

Jun 26, 2026

Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda - BioPharma Dive

Jun 26, 2026

What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI

Jun 26, 2026

Jun 25, 2026

Alkermes Public Limited Company Actuals & Estimates (NASDAQ:ALKS) - TradingView

Jun 25, 2026

ALKS Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Alkermes stock hits 52-week high at 51.77 USD By Investing.com - Investing.com South Africa

Jun 25, 2026

Alkermes stock hits 52-week high at 51.77 USD - Investing.com

Jun 25, 2026

Jun 24, 2026

Liquidity Mapping Around (ALKS) Price Events - Stock Traders Daily

Jun 24, 2026

Alkermes Jumps 6.9% After Needham Maintains Buy - AlphaStreet

Jun 24, 2026

ALKS Maintained by Needham -- Price Target Raised to $61.00 - GuruFocus

Jun 24, 2026

Jun 23, 2026